

# Antibiogram - 2023

Woodstock Hospital

# Woodstock Hospital

## **A Guide to Interpreting the Antibiogram**

- The antibiogram is an annual cumulative report of the antimicrobial susceptibility rates of common pathogens recovered from patients receiving care at Woodstock Hospital and is to be used as a resource to inform empirical antimicrobial therapy.
- Susceptibility rates are calculated from the compilation of susceptibility results from all 'first' clinical isolates of a specific pathogen recovered from an individual patient per 30-day period. The rationale for this referral period is based on the need to represent 'wild-type' susceptibility profiles and avoid over-representing antimicrobial resistance that may develop de novo during a patient's prolonged hospital stay.
- Susceptibility rates for pathogens or clinical scenarios represented by less than 30 isolates are not calculated due to their limited statistical significance and interpretive value.
- The appropriateness of empiric therapy is highlighted using a colour range that corresponds to susceptibility rates. Green, 80-100%; Yellow, 70-79%; Red, <70%.

# Antibiogram - 2023

## Woodstock Hospital

Organism	Number of Isolates	Ampicillin	Amoxicillin-Clavulanate	Piperacillin-Tazobactam	Cloxacillin	Cephalexin (urinary tract)	Cefazolin	Ceftriaxone	Ceftazidime	Imipenem	Meropenem	Ciprofloxacin	Clindamycin	Doxycycline	Gentamicin	Tobramycin	TMP-SMX	Vancomycin
<i>Escherichia coli</i>	668	62	92			90	75	91		100		78			95	95	83	
<i>Klebsiella pneumoniae</i> complex	141		92			85	80	86		100		85			93	91	84	
<i>Proteus mirabilis</i>	64	80	92					97			100	86			80	80	83	
<i>Klebsiella oxytoca</i>	45		91					93		100		98			100	98	98	
<i>Pseudomonas aeruginosa</i>	84			86					87	69	89	80				93		
<i>Staphylococcus aureus</i> (incl. MRSA)	182				68								82	100			99	100
MRSA	58				0								93	100			100	100

*Enterobacter*, *Citrobacter*, *Klebsiella aerogenes* and *Serratia* species are intrinsically resistant to ampicillin, cefazolin, and cefuroxime and may develop resistance to broader-spectrum beta-lactams during prolonged beta-lactam therapy.

<https://www.lhsc.on.ca/palm/labs/microbiology.html#main-content>